Showing 8051-8060 of 8647 results for "".
- CRST: 2019 Year in Focushttps://modernod.com/news/2019-year-in-focus/2477197/Fueled by an influx of investment capital in recent years and a streamlined regulatory review process, the number of ophthalmic products approved or introduced in 2019 continued to rise steadily throughout the year. According to recent figures from pharmaceutical market research company Strategic
- 10 Best Foods to Protect Your Eyesighthttps://modernod.com/news/10-best-foods-to-protect-your-eyesight/2477196/As we approach the new year and new decade, many of us are focused on a new vision for our lives. But in order to protect the vision we have, experts say that eating certain foods can help us preserve our eyesight and prevent ocular diseases. “Antioxidants have been long known to hel
- Novartis Receives Permanent J-code for Beovuhttps://modernod.com/news/novartis-receives-permanent-j-code-for-beovu/2477192/Novartis announced that it has received a permanent J-code for Beovu (brolucizumab-dbll) injection, effective January 1, 2020. With the permanent J-code, retina specialists may now receive more timely reimbursement for Beovu injections, facilitating access for appropriate patients to this
- 5,736 of the World’s Poorest People Received the Gift of Sight in 2019 at the Tej Kohli Cornea Institutehttps://modernod.com/news/5736-of-the-worlds-poorest-people-received-the-gift-of-sight-in-2019-at-the-tej-kohli-cornea-institute/2477189/On the fourth anniversary of the Tej Kohli Cornea Institute in Hyderabad, the Tej Kohli Foundation has renewed its commitment of $14 million of funding from 2020. During 2019, 5,736 individuals were cured of blindness or severe visual impairment at The Tej Kohli Cornea Institute, according to new
- Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Diseasehttps://modernod.com/news/nicoxs-ncx-4251-meets-primary-endpoint-in-phase-2-blepharitis-trial-and-shows-promising-efficacy-in-dry-eye-disease/2477187/Nicox SA announced that NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, has met the primary objective of its U.S. multicenter, dose escalating, first-in-human, phase 2 clinical trial (referred to as ‘Danube’) evaluating the safety and tolerability of NCX 4
- With EyeCare Partners Deal, Swiss Firm Sees a Base for ‘Organic Growth, Expansion and Consolidation’ of U.S. Vision Markethttps://modernod.com/news/with-eyecare-partners-deal-swiss-firm-sees-a-base-for-organic-growth-expansion-and-consolidation-of-u-s-vision-market/2477176/In the second major acquisition of an eyecare practice management group this year, the Switzerland-based Partners Group announced Monday morning that it has agreed to make a significant investment in EyeCare Partners LLC (ECP). FFL Partners announced separately that it was selling the stake it ha
- Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-cohesive-ophthalmic-viscosurgical-device-ovd/2477174/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics. “This is the second new OVD th
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra
- Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-trading-halted-today-fda-committee-meeting-to-discuss-teprotumumab-for-thyroid-eye-disease/2477167/Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss
- FocalPoint Holdings Partners with GreenSky Patient Solutions to Enable 8,000 Ophthalmology Providers to Provide Patient Financinghttps://modernod.com/news/focalpoint-holdings-partners-with-greensky-patient-solutions-to-enable-8000-ophthalmology-providers-to-provide-patient-financing/2477162/FocalPoint Holdings announced a partnership with GreenSky Patient Solutions which enables FocalPoint Holdings’ network of 8,000 ophthalmology and optometry providers to offer flexible financing solutions, including revolving credit and installment loan products. “As the healthcare system i